This New Histamine Treatment Helped 89% of Patients
In a Nutshell
A landmark 2025 case series showed that microdosed GLP-1 medications (semaglutide or tirzepatide) produced an 89% response rate in patients with mast cell activation syndrome who had previously failed an average of 13 other treatments. The therapy works by directly stabilizing mast cells and modulating multiple immune pathways, often improving symptoms like fatigue, brain fog, GI issues, and hives within hours to days—independent of weight loss. Dosing starts at 10-25% of standard weight-loss amounts (e.g., 0.25 mg tirzepatide weekly) with slow titration, and only 3 of 47 patients discontinued due to side effects.
These notes were generated by AI and may contain inaccuracies.
The Canadian Journal of Gastroenterology and Hepatology cites that between 30 and 55% of patients with digestive symptoms might have histamine intolerance. This condition involves chronic inflammation that underlies and causes their symptoms. The signs and symptoms of histamine intolerance include digestive symptoms, reflux, food reactions, loose bowels, constipation, diarrhea, bloating, and distension. Given histamine's systemic effects, symptoms can also include fatigue, brain fog, low mood, insomnia, and elevated heart rate. These symptoms occur due to histamine's impact on the autonomic nervous system. Additional symptoms include flushing, skin reactions like hives and rashing, and joint pain.
A challenge many with histamine intolerance face is an incomplete resolution of their symptoms. For those not responding to dietary changes, lifestyle changes, or any number of supplemental and natural health interventions, a very relevant paper was recently published. This landmark study demonstrated an 89% response rate in reducing symptoms for individuals with chronic inflammatory symptoms who had not fully responded to a number of other therapies. Many of these patients improved within hours to days.
The root cause or one major root cause of these unresponsive symptoms involves having a healthy gut, including a healthy gut border and healthy microbiota. When this ecosystem is healthy, there is no triggering of the mast cell, an important immune sentinel cell. When there is dysbiosis, which could be SIBO, imbalances of bacteria without overgrowth per se, fungal overgrowth like candida, or even a parasitic infection, then levels of histamine increase, inflammation increases. This triggers the mast cells to release further histamine and propagate inflammation, leading to dysfunction in the lining of the gut.
The study used a peptide known as a GLP-1, which is a naturally occurring peptide produced in the human gut. GLP-1 regulates blood sugar and appetite and is often discussed in the context of weight loss. However, when used in a microdose, a very low dose, there can be a substantial impact on inflammation and the mast cells. GLP-1 peptides stabilize the mast cells directly. Mast cells release histamine along with a myriad of other inflammatory mediators including prostaglandins and leukotrienes. GLP-1s directly bind to a GLP-1 receptor on the mast cells. Additionally, GLP-1s modulate a number of other immune cells including T cells, B cells, natural killer T cells or NKT cells, macrophages, and eosinophils. GLP-1s also modulate the NF-κB signaling pathway, which is a master regulator of inflammatory gene expression. This gets to a cellular level of reducing the genetic expression of proteins that produce inflammatory cytokines.
A 2025 case series published by Dr. Leonard Weinstock, Dr. Tanya Dempsey, and Dr. Lawrence Afrin examined 47 patients with disordered mast cell activity or MCAS. These patients on average had failed 13 other treatments, yet responded to a low dose of a GLP-1 medication, either semaglutide or tirzepatide, used at a small or microdose. 89% demonstrated clinical benefit, with many having improvements within hours to days. The reduction of symptoms was seen independent and before any weight loss. The symptoms that improved included fatigue, brain fog, pain, gastrointestinal symptoms including nausea and food intolerances, improvements in hives, flushing, itching, dysautonomia or dysregulation of the autonomic nervous system, POTS-like symptoms, blood sugar instability, and improvement in overall functional capacity.
Dr. Leonard Weinstock stated: "I have done research project with 60 patients, and at this point, uh with the follow-up I've got approximately 50% seem to be benefiting, but the amazing thing is to what degree. So, that all of their symptoms can get better if they're going to respond if they're responders. Uh we do see many improvements across the spectrums. And you may well be hearing about some of the systematic improvements, neuropsychiatric, constitutional, dermatological, GI, but also body pain, cardiovascular, pulmonary, GYN, and they tip atopic conditions."
Dr. Weinstock also noted: "Microdosing seems to be helpful. There's probably, however, a particular phenotype that is the best one to offer the GLP-1 therapy. And it's not necessarily obesity because I've had a patient who was refractory to many disorders including hydroxyurea and imatinib, and on very low doses this 100-lb woman was able to actually gain weight because she could eat all kinds of food that she wasn't able to eat before."
Dr. Alana Grevich stated: "I'm Dr. Alana Grevich and I am using a fair amount of GLP-1 and GIPs in my private practice for a lot of conditions including and especially mast cell activation. What I am seeing is that the GLP and GIP ones and my preference is using the combo GLP GIP is acting as a very very strong anti-inflammatory to decrease a lot of the secondary issues that happen from a mast cell activation patient. I'm seeing that there is a decrease in inflammatory process, a decrease in histamine, a decrease in reactivity, and as a whole it seems to be a good adjunctive care to help support these patients to develop some stability for their overall disease."
Dr. Jake Monfelt and Dr. Scott Spradling from the clinical team echoed the same sentiment. Dr. Spradling had one case in particular for whom someone who had really debilitating spells of anxiousness had a remarkable response to low-dose tirzepatide.
There were two case reports in individuals with chronic spontaneous urticaria where one patient saw complete resolution in 3 weeks and the other patient saw a pretty remarkable reduction in their symptoms. There was another case report published with chronic systemic mastocytosis where the individual became symptom-free for the first time in years with improvements starting immediately after her first dose. The improvements included reductions in rashes, flushing, itching, diarrhea, easily bruising, headaches, fatigue, and allergy-like reactions, and she remained symptom-free at 6 months.
A similar peptide was used in a study of 166 IBS patients looking at placebo versus a different GLP-1 medication, documenting a 50% response rate over placebo. There are also case reports documenting improvements for asthma, atopic dermatitis and eczema, and psoriasis.
There are two main medications that can be used: semaglutide and tirzepatide. When using for mast activation or chronic inflammation, it is a microdose, defined roughly as 10% to 25% of the standard dose used for weight loss. The goal is to slowly titrate this, starting low and going slow, which helps mitigate the transient side effects and allows finding the minimal effective dose.
One quote from the paper states: "Some patients clearly respond quite well at doses below approved starting doses, suggesting efforts to identify the individual patient's minimum effective dose of each drug may be a better strategy than identifying the maximum tolerated dose."
Tirzepatide is administered as a subcutaneous injection at a tiny pinch of belly fat. The standard dose is 2.5 mg weekly. The MCAS or immune anti-inflammatory dose is 0.25 mg weekly. Titrating slowly involves waiting 2 to 3 weeks and then increasing the dose, often doubling, and then waiting another 2 to 3 weeks.
Semaglutide has two forms: oral and injectable. For oral, the standard dose is 3 mg once daily. The MCAS dose would be about 0.3 mg daily. Subcutaneous dosing is 0.25 mg weekly, with the MCAS or anti-inflammatory dose being 0.125 mg once weekly.
The paper did not document any major adverse events at the microdoses used. Some had transient flares, which can occur anytime the immune system is modulated. Only three out of the 47 discontinued due to side effects. The most common side effects reported are gastrointestinal, including nausea, constipation, diarrhea, abdominal pain, and indigestion. These side effects mitigate and normalize over time and can be reduced if starting low and going slow. Tirzepatide has been demonstrated to have the lowest incidence of side effects.
Both peptides are prescription only. Research-only labs sell to anybody, but these peptides are not intended for human use. Pharmacies held to appropriate regulatory options should be used. Cora MD offers convenient online prescribing and is privy to microdosing as one of the core components of their offering. The company was started by a former pro boxer who found major response from tirzepatide for his chronic inflammatory symptoms.
The landmark publication by Weinstock, Afrin, and Dempsey shows how GLP-1s at a microdose can be beneficial for chronic inflammation, particularly in those who have not fully responded to other treatments. Finding a functional medicine provider well trained in mast cell activation syndrome is recommended. The three doctors at the clinic are members of the International Society of Mast Cell Activation Syndrome.
Keep Dr. Michael Ruscio, DC, DNM in your library
Save the videos and channels worth coming back to, and find them again in one place.
